LRMR
Larimar Therapeutics Inc
NASDAQ: LRMR · HEALTHCARE · BIOTECHNOLOGY
$2.54
+6.28% today
Updated 2026-10-28
Market cap
$244.13M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.99
Dividend yield
—
52W range
$2 – $6
Volume
1.4M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.0
Quality
B3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-6.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$14.40
+466.93%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.04x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -6.60 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-44.16M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-34.18M | $-36.95M | $-80.60M | $-165.67M | $-32.78M |
| EPS | — | — | — | — | $-1.99 |
| Free cash flow | $-27.67M | $-33.62M | $-71.28M | $-113.29M | $-44.16M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-29 | HARLOW, JOHN B. JR. | Buy | 800,000 | — |
| 2026-09-29 | HARLOW, JOHN B. JR. | Buy | 50,000 | — |
| 2026-07-06 | HAMILTON, THOMAS EDWARD | Buy | 50,000 | $3.34 |
Peer comparison
Smart narrative
Larimar Therapeutics Inc trades at $2.54. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -6.60, it sits in the distress.
Frequently asked questions
What is Larimar Therapeutics Inc's stock price?
Larimar Therapeutics Inc (LRMR) trades at $2.54.
Is Larimar Therapeutics Inc overvalued?
Larimar Therapeutics Inc carries a Smart Value Score of 24/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Larimar Therapeutics Inc (LRMR)?
The 12-month analyst consensus target is $14.40, about 466.9% above the current $2.54. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Larimar Therapeutics Inc's Altman Z-Score is -6.60, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-135.50%
Beta0.69
50D MA$3.39
200D MA$3.83
Shares out0.10B
Float0.06B
Short ratio—
Avg volume1.4M
Performance
1 week-17.02%
1 month-20.95%
3 months+3.93%
YTD-16.80%
1 year-6.21%
3 years—
5 years—